Merck KGAA/Pfizer Discontinue Phase III Avelumab/Talazoparib Combo Study In Ovarian Cancer
The changing competitive landscape in ovarian cancer, as well as disappointing earlier results in the condition, has led to the big pharma alliance ending the Phase III JAVELIN Ovarian PARP 100 study.
You may also be interested in...
European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.
Competing combination therapies may soon be battling for attention as first-line therapies for advanced or metastatic renal cell carcinoma, with Merck & Co being the latest big pharma to release more data on the Keytruda/Inlyta combo in the setting.